GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

THE ARM FOR THE LANCASTER COUNTY ECONOMY. THIS IS FOR GSK, THE LARGEST INVESTMENT IN MANUFACTURING WE’VE EVER DONE IN THE UNITED STATES. THE $800 MILLION WILL BE USED TO EXPAND GSK’S MARIETTA ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), following a string of exits by companies including Pfizer, UCB, WuXi AppTec and ...

GlaxoSmithKline (GSK) has firmly acquired the number one position in the Egyptian pharmaceutical market since 2009 and is likely to maintain the grip at least until the end of 2011. GSK’s ...

After making a splash in the U.K. earlier this year, GSK is laying out plans for its biggest U.S. manufacturing investment yet. GSK is investing up to $800 million to double the size and capacity ...

Moderna to defend against GSK's claims, spokesperson says GSK seeks unspecified monetary damages from Moderna A spokesperson for Massachusetts-based Moderna said the company was aware of the ...

GSK is pumping 50 million pounds sterling (about $65 million) into a five-year collaboration with the University of Cambridge and Cambridge University Hospitals to more precisely treat immune ...

This time, we have GSK (GSK) "GSK" filing a lawsuit against Moderna (NASDAQ:MRNA) accusing them of patent infringement on their lipid nanoparticle (LNP) technology, which is used in mRNA therapeutics.

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...

The market expects GSK (GSK) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is ...